UY27682A1 - Composiciones farmacéuticas - Google Patents

Composiciones farmacéuticas

Info

Publication number
UY27682A1
UY27682A1 UY27682A UY27682A UY27682A1 UY 27682 A1 UY27682 A1 UY 27682A1 UY 27682 A UY27682 A UY 27682A UY 27682 A UY27682 A UY 27682A UY 27682 A1 UY27682 A1 UY 27682A1
Authority
UY
Uruguay
Prior art keywords
soluble cellulose
cellulose ether
water
pharmaceutical compositions
agent
Prior art date
Application number
UY27682A
Other languages
English (en)
Inventor
Paul R Gellert
Maarcel De Matas
Michael D Parker
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767732&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY27682(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0204392A external-priority patent/GB0204392D0/en
Priority claimed from GB0212462A external-priority patent/GB0212462D0/en
Priority claimed from GB0213267A external-priority patent/GB0213267D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UY27682A1 publication Critical patent/UY27682A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición farmacéutica que comprende 4-(3,-cloro-4,- fluoroanilino) -7-metoxo- 6- (3-morfollinopropoxi) quinazolina o una sal farmacéuticamente aceptable de la misma (el Agente) y un éter de celulosa soluble en agua o éster de un éter de celulosas soluble en agua. El éter de celulosa soluble un agua o éter de un éter de celulosa soluble en agua presente en la composición inhibe la velocidad de precipitación del Agente de partir de la solución.
UY27682A 2002-02-26 2003-02-26 Composiciones farmacéuticas UY27682A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0204392A GB0204392D0 (en) 2002-02-26 2002-02-26 Pharmaceutical compound
GB0212462A GB0212462D0 (en) 2002-05-30 2002-05-30 Pharmaceutical compound
GB0213267A GB0213267D0 (en) 2002-06-11 2002-06-11 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
UY27682A1 true UY27682A1 (es) 2003-10-31

Family

ID=27767732

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27682A UY27682A1 (es) 2002-02-26 2003-02-26 Composiciones farmacéuticas

Country Status (30)

Country Link
US (2) US20050163835A1 (es)
EP (1) EP1480679B1 (es)
JP (1) JP4544863B2 (es)
KR (2) KR101002374B1 (es)
CN (1) CN1326569C (es)
AR (1) AR038848A1 (es)
AT (1) ATE362771T1 (es)
AU (1) AU2003208444B2 (es)
BR (1) BRPI0307786B8 (es)
CA (1) CA2476587C (es)
CO (1) CO5601038A2 (es)
CY (1) CY1108026T1 (es)
DE (1) DE60313956T2 (es)
DK (1) DK1480679T3 (es)
ES (1) ES2286406T3 (es)
HK (1) HK1070585A1 (es)
IL (2) IL163642A0 (es)
IS (1) IS2462B (es)
MX (1) MXPA04008307A (es)
MY (1) MY135609A (es)
NO (1) NO328658B1 (es)
NZ (1) NZ534513A (es)
PL (1) PL208114B1 (es)
PT (1) PT1480679E (es)
RU (1) RU2318518C2 (es)
SA (1) SA03240043B1 (es)
TW (1) TWI271193B (es)
UA (1) UA76325C2 (es)
UY (1) UY27682A1 (es)
WO (1) WO2003072139A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534871A (en) 2002-02-26 2007-05-31 Astrazeneca Ab Novel crystalline forms of the anti-cancer compound ZD1839
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
JP4205757B2 (ja) 2004-05-06 2009-01-07 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ４−フェニルアミノ−キナゾリン−６−イル−アミド
WO2007031933A2 (en) 2005-09-12 2007-03-22 Actelion Pharmaceuticals Ltd Stable pharmaceutical composition comprising a pyrimidine-sulfamide
EP3954715A3 (en) 2006-10-27 2022-05-04 Capsugel Belgium NV Hydroxypropyl methyl cellulose hard capsules and process of manufacture
AU2008258627A1 (en) * 2007-06-06 2008-12-11 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
US8728516B2 (en) * 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
TWI471321B (zh) * 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Ｂｃｌ－２族群抑制劑之口服醫藥劑型
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
SG177309A1 (en) * 2009-07-02 2012-02-28 Wyeth Llc 3-cyanoquinoline tablet formulations and uses thereof
SG181916A1 (en) * 2009-12-22 2012-08-30 Abbott Lab Abt-263 capsule
JP4574742B1 (ja) * 2010-04-08 2010-11-04 有限会社ミールジャパン プロポリス組成物
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
KR102095698B1 (ko) 2010-10-29 2020-04-01 애브비 인코포레이티드 아폽토시스―유도제를 포함하는 고체 분산체
EP2643322B1 (en) 2010-11-23 2017-08-30 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
WO2012071340A1 (en) 2010-11-23 2012-05-31 Metamagnetics Inc. Antenna module having reduced size, high gain, and increased power efficiency
HUE031267T2 (en) 2010-11-23 2017-06-28 Abbvie Ireland Unlimited Co Methods of treatment using selective BCL-2 inhibitors
CN102631347B (zh) * 2012-05-03 2014-06-25 石药集团中奇制药技术（石家庄）有限公司 一种吉非替尼药物组合物及其制备方法
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
KR101332829B1 (ko) * 2013-05-31 2013-11-27 재단법인 통합의료진흥원 보중익기탕을 포함하는 폐암 치료용 조성물
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
KR101721831B1 (ko) * 2014-11-06 2017-03-31 주식회사 종근당 로베글리타존을 함유하는 경구 투여용 약제학적 조성물
EP3233064A1 (en) 2014-12-19 2017-10-25 Synthon BV Pharmaceutical composition comprising gefifinib
FI3263110T3 (fi) * 2015-02-26 2023-07-25 Takeda Pharmaceuticals Co Tabletti, joka käsittää metoksiureajohdannaista ja mannitolipartikkeleita
KR101739731B1 (ko) * 2015-12-31 2017-05-25 환인제약 주식회사 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물
CN108096251B (zh) * 2016-11-24 2021-11-16 江苏恒瑞医药股份有限公司 一种吉非替尼药物组合物及其制备方法
CN107007562B (zh) * 2017-02-16 2020-10-27 南京优科制药有限公司 一种吉非替尼片剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608063A (en) * 1969-08-15 1971-09-21 Gilbert S Banker Molecular drug entrapment process and compositions
US4178376A (en) * 1977-01-21 1979-12-11 Interx Research Corporation Method for inducing rapid therapeutically effective antimalarial levels of certain selected conventional antimalarials
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9207988D0 (en) * 1992-04-10 1992-05-27 Smithkline Beecham Plc Topical composition
JPH09501947A (ja) * 1993-08-30 1997-02-25 ワーナー−ランバート・コンパニー 改良された錠剤コーティング方法
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB2306885B (en) * 1995-11-08 1999-07-14 Reckitt & Colmann Prod Ltd Supersaturated Pharmaceutical Compositions
JP4713698B2 (ja) * 1997-03-05 2011-06-29 スージェン， インク． 疎水性薬剤の処方
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
KR100397792B1 (ko) * 2001-06-28 2003-09-13 한국과학기술연구원 4-(페닐아미노)-[1,4]디옥사노[2,3-ｇ]퀴나졸린 유도체 및그의 제조방법
NZ534871A (en) * 2002-02-26 2007-05-31 Astrazeneca Ab Novel crystalline forms of the anti-cancer compound ZD1839
KR20050104152A (ko) 2004-04-28 2005-11-02 최승호 경구용 약물의 흡수를 증진하는 약제학적 조성물

Also Published As

Publication number Publication date
DE60313956T2 (de) 2008-05-15
ES2286406T3 (es) 2007-12-01
US20050163835A1 (en) 2005-07-28
AU2003208444B2 (en) 2006-10-26
JP4544863B2 (ja) 2010-09-15
KR20100090726A (ko) 2010-08-16
MXPA04008307A (es) 2004-11-26
TW200304379A (en) 2003-10-01
AR038848A1 (es) 2005-01-26
KR101002374B1 (ko) 2010-12-17
RU2004129280A (ru) 2005-06-10
CO5601038A2 (es) 2006-01-31
KR20040088524A (ko) 2004-10-16
IL163642A0 (en) 2005-12-18
EP1480679A1 (en) 2004-12-01
WO2003072139A1 (en) 2003-09-04
TWI271193B (en) 2007-01-21
HK1070585A1 (en) 2005-06-24
PL372215A1 (en) 2005-07-11
NO328658B1 (no) 2010-04-19
BRPI0307786B1 (pt) 2018-03-13
RU2318518C2 (ru) 2008-03-10
DE60313956D1 (de) 2007-07-05
BRPI0307786B8 (pt) 2021-05-25
EP1480679B1 (en) 2007-05-23
CA2476587C (en) 2010-05-04
IL163642A (en) 2007-07-24
PL208114B1 (pl) 2011-03-31
CN1638805A (zh) 2005-07-13
US20090186890A1 (en) 2009-07-23
AU2003208444A1 (en) 2003-09-09
SA03240043B1 (ar) 2007-05-06
IS7420A (is) 2004-08-24
MY135609A (en) 2008-05-30
PT1480679E (pt) 2007-07-18
JP2005523293A (ja) 2005-08-04
DK1480679T3 (da) 2007-09-03
IS2462B (is) 2008-11-15
UA76325C2 (uk) 2006-07-17
CA2476587A1 (en) 2003-09-04
BR0307786A (pt) 2004-12-07
NO20043866L (no) 2004-09-15
CY1108026T1 (el) 2013-09-04
CN1326569C (zh) 2007-07-18
ATE362771T1 (de) 2007-06-15
NZ534513A (en) 2007-04-27

Similar Documents

Publication Publication Date Title
UY27682A1 (es) Composiciones farmacéuticas
AR045161A1 (es) Derivados de quinazolina
JP2005532372A5 (es)
AR035482A1 (es) Uso de un compuesto de cianoquinolina para la manufactura de un medicamento para tratar o inhibir polipos colonicos
TW200518753A (en) Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
MA27265A1 (fr) Formulations d'agoniste opioide a antagoniste liberable et sequestre
GEP20053595B (en) Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment
TNSN06032A1 (en) Pyridazine derivatives and their use as therapeutic agents
EA200300081A1 (ru) Гидрогель-управляемая лекарственная форма
RS52577B (en) ONE-DAY OXYCODON FORMULATIONS
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
ES2721899T3 (es) Composiciones farmacéuticas que comprenden fentanilo para su administración intranasal
ATE415410T1 (de) Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheiten
NZ510887A (en) Formulations of fexofenadine for ocular and nasal delivery
AR034343A1 (es) Combinaciones farmaceuticas
BR0007294A (pt) Formulações farmacêuticas aperfeiçoadas
WO2005011647A3 (en) Pharmaceutical composition
FR2850023B1 (fr) Medicaments pour le systeme nerveux
AR044861A1 (es) Una composicion para pelicula consumible via oral para suministrar agentes antiplaca y refrescantes del aliento
EA200300110A1 (ru) Композиция элетриптана в виде частиц
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
BR0307320A (pt) Sistema de liberação osmótico
ATE401900T1 (de) Verwendung von polyethylenglycol ( peg ) zur herstellung eines medikamentes zur behandlung von verstopfung
AR032614A1 (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
ATE363909T1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160812